Scarica l'app Stockscreener
794.19
1.67%
-13.52
Pre-mercato:
792.00
-2.19
-0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In? - simplywall.st
Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)? Levi & Korsinsky Urges Investors to Act Before September 14, 2026 - ACCESS Newswire
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? - The Motley Fool
Why Is Regeneron (NASDAQ:REGN) Drawing Attention After Market Drop? - Kalkine Media
Wealthfront Advisers LLC Invests $4.37 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock holds above $826 as FDA approval and lawsuit reshape risk picture - Ad-hoc-news.de
Tocqueville Asset Management L.P. Acquires Shares of 3,315 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Madison Asset Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Ceredex Value Advisors LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Enters New Healthcare Focus - Kalkine Media
Regeneron stock jumps on FDA approval for ultra-rare bone disorder drug - Ad-hoc-news.de
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class ActionContact SueWallSt - Morningstar
Advanz Looks To Nix Regeneron, Bayer Eye Med Patents - Law360
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For The First Adult FOP Treatment - simplywall.st
Regeneron to challenge Ipsen as FDA clears bone disease drug - BioPharma Dive
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug - Yahoo Finance
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN Looks 5.6% Undervalued on GF Value™ Amid FDA Approval Boost - GuruFocus
REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities LawsuitContact Levi & Korsinsky - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - PR Newswire
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Benzinga
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT - GlobeNewswire
FDA nod for Regeneron’s Pasatru for ultra-rare genetic disorder FOP - The Pharma Letter
Johnson Financial Group Inc. Buys Shares of 3,250 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
1,311 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Meeder Advisory Services Inc. - MarketBeat
E Fund Management Co. Ltd. Makes New $3.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
DCF Advisers LLC Purchases New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US FDA approves Regeneron's rare bone disorder drug - Reuters
Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News - Yahoo Finance
REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses - Morningstar
Regeneron (REGN) Results Review: Profit Per Share Clears Its Benchmark in the Current Update; Closing Reaction - Vinanet
TLX: Revenue up 22% to $477.3M, net profit $38.3M, boosted by U.S. sales and Regeneron deal - TradingView
US FDA approves Regeneron’s rare bone disorder drug - KELO-AM
Ninth Circuit Revives Regeneron Kickback Whistleblower Lawsuit - Bloomberg Law News
Pasatru’s FDA Approval Puts Regeneron’s Rare-Disease Playbook To The Test - insights.citeline.com
Regeneron Announces Investor Conference Presentations - marketscreener.com
Why Does Regeneron Pharmaceuticals (NASDAQ:REGN) Merit A Fresh Look? - Kalkine Media
REGN Looks 4.9% Undervalued on GF Value™ After FDA Approval - GuruFocus
Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition - marketscreener.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP - Investing.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With Fibrodysplasia Ossificans Progressiva - Quiver Quantitative
Regeneron rare bone disorder therapy approved (REGN:NASDAQ) - Seeking Alpha
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact Levi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 52-Week HighWhat's Next? - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD By Investing.com - Investing.com Australia
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD - Investing.com
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Oxbow Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
M. Kulyk & Associates LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Meeder Asset Management Inc. Invests $4.46 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Pallas Capital Advisors LLC Takes $1.20 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Great Lakes Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Danske Bank A S Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Global Retirement Partners LLC Makes New $975,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock holds near a 52-week high after a strong quarter. - Ad-hoc-news.de
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact The Gross Law Firm - Morningstar
Promising Biotech Stocks To Watch TodayAugust 18th - MarketBeat
Regeneron ends eye disease study due to antibody’s safety profile - BioSpace
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - TMX Newsfile
Regeneron ends eye disease study after antibody shows ‘unfavorable’ risk/benefit profile - BioSpace
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
3.37%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):